Chondrosarcoma Overview

Save information for later
Sign Up

Learn About Chondrosarcoma

View Main Condition: Brain Tumor

What is the definition of Chondrosarcoma?
Chondrosarcoma is a rare, slow-growing form of bone cancer that develops in the bones or the cartilage. The cartilage is the connective tissue from which most bones develop. Chondrosarcomas appear in bones or cartilage at the base of the skull, arms, scapula, ribs, pelvis, knee, femur (thighbone), or tibia.
What are the symptoms of Chondrosarcoma?
Symptoms of chondrosarcoma depend on the cartilage or bone that is involved and include the appearance of a large mass on the affected bone, swelling and pressure surrounding the mass, muscle wasting, gradually increasing pain not relieved with rest, constant pain that worsens at night, and fracture of the affected bone. A chondrosarcoma that appears on the spine may cause weakness, numbness, and an inability to control the release of urine (incontinence) or bowels.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Chondrosarcoma?
Treatment for chondrosarcoma depends on a patient’s age, overall health, medical history, the stage and location of the cancer, and may include surgery to remove the tumor, bone reconstructive surgery, amputation, radiation therapy, chemotherapy, and physical therapy.
Who are the top Chondrosarcoma Local Doctors?
Dr. Brian E. Brigman
Orthopedics
Dr. Brian E. Brigman
Orthopedics

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (80.1 mi)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Brigman is an Orthopedics provider in Durham, North Carolina. Dr. Brigman and is rated as an Elite provider by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Bone Tumor, Chondrosarcoma, Myringotomy, and Bone Graft. Dr. Brigman is currently accepting new patients.

Dr. Benjamin A. Alman
Pediatric Orthopedics | Orthopedics
Dr. Benjamin A. Alman
Pediatric Orthopedics | Orthopedics
40 Duke Medicine Cir, 
Durham, NC 
 (80.1 mi)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Benjamin Alman is a Pediatric Orthopedics specialist and an Orthopedics provider in Durham, North Carolina. Dr. Alman and is rated as a Distinguished provider by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Desmoid Tumor, Chondrosarcoma, Ollier Disease, Undifferentiated Pleomorphic Sarcoma, and Hip Replacement. Dr. Alman is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Richard F. Riedel
Oncology
Dr. Richard F. Riedel
Oncology

Duke Health Integrated Practice Inc

2301 Erwin Rd, 
Durham, NC 
 (80.2 mi)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Riedel is an Oncologist in Durham, North Carolina. Dr. Riedel and is rated as a Distinguished provider by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Desmoid Tumor, and Angiosarcoma. Dr. Riedel is currently accepting new patients.

View All Doctors
What are the latest Chondrosarcoma Clinical Trials?
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Enrollment Status: Recruiting
Publish Date: February 17, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1 (IDH1) gene-mutated, locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resect...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors
A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors
Who is this study for: Patients with advanced solid tumors
Enrollment Status: Recruiting
Publish Date: February 10, 2025
Intervention Type: Drug, Biological
Study Drugs: IPN60090, Pembrolizumab
Study Phase: Phase 1

Summary: To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.

View All Clinical Trials